173 related articles for article (PubMed ID: 31432687)
1. Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia.
Faught BM; Soulban G; Yeaw J; Maroun C; Coyle K; Schaffer S; DeKoven M
J Comp Eff Res; 2019 Oct; 8(13):1111-1123. PubMed ID: 31432687
[No Abstract] [Full Text] [Related]
2. A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia.
Wallace SL; St Martin B; Lee K; Sokol ER
Am J Obstet Gynecol; 2020 Dec; 223(6):890.e1-890.e12. PubMed ID: 32562659
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
Wurz GT; Kao CJ; DeGregorio MW
Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
[TBL] [Abstract][Full Text] [Related]
4. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
5. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
Portman DJ; Bachmann GA; Simon JA;
Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
[TBL] [Abstract][Full Text] [Related]
6. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy.
Nappi RE; Murina F; Perrone G; Villa P; Biglia N
Minerva Ginecol; 2017 Aug; 69(4):370-380. PubMed ID: 28398023
[TBL] [Abstract][Full Text] [Related]
7. Ospemifene for the treatment of dyspareunia in postmenopausal women.
Paton DM
Drugs Today (Barc); 2014 May; 50(5):357-64. PubMed ID: 24918836
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
Simon J; Portman D; Mabey RG;
Maturitas; 2014 Mar; 77(3):274-81. PubMed ID: 24411556
[TBL] [Abstract][Full Text] [Related]
9. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
[TBL] [Abstract][Full Text] [Related]
11. Profile of ospemifene in the breast.
Berga SL
Reprod Sci; 2013 Oct; 20(10):1130-6. PubMed ID: 23945733
[TBL] [Abstract][Full Text] [Related]
12. Assessment of ospemifene or lubricants on clinical signs of VVA.
Constantine G; Graham S; Koltun WD; Kingsberg SA
J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
[TBL] [Abstract][Full Text] [Related]
13. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
DeGregorio MW; Zerbe RL; Wurz GT
Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
[TBL] [Abstract][Full Text] [Related]
15. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy.
Bruyniks N; Biglia N; Palacios S; Mueck AO
Climacteric; 2017 Jun; 20(3):195-204. PubMed ID: 28267367
[TBL] [Abstract][Full Text] [Related]
16. Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia.
Eder SE
Womens Health (Lond); 2014 Sep; 10(5):499-503. PubMed ID: 25335541
[TBL] [Abstract][Full Text] [Related]
17. Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
Simon JA; Altomare C; Cort S; Jiang W; Pinkerton JV
J Womens Health (Larchmt); 2018 Jan; 27(1):14-23. PubMed ID: 29064335
[TBL] [Abstract][Full Text] [Related]
18. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
Pinkerton JV; Kagan R
Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
[TBL] [Abstract][Full Text] [Related]
19. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy.
Nappi RE; Panay N; Bruyniks N; Castelo-Branco C; De Villiers TJ; Simon JA
Climacteric; 2015 Apr; 18(2):233-40. PubMed ID: 25335119
[TBL] [Abstract][Full Text] [Related]
20. Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women.
Constantine GD; Kagan R; Miller PD
Menopause; 2016 Jun; 23(6):638-44. PubMed ID: 27045700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
